시장보고서
상품코드
2112263

바이오의약품 제3자물류 시장 규모, 점유율 및 동향 분석 보고서 : 공급망별, 서비스 유형별, 지역별 및 부문별 예측(2026-2033년)

Biopharmaceutical Third-party Logistics Market Size, Share & Trends Analysis Report By Supply Chain (Cold Chain Logistics, Non-cold Chain Logistics), By Service Type (Transportation, Warehousing & Storage), By Region, And Segment Forecasts, 2026 - 2033

발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ₩ 8,488,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ₩ 9,915,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ₩ 12,768,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

바이오의약품 제3자 물류 시장 요약

세계의 바이오의약품 제3자물류(3PL) 시장 규모는 2025년에 1,520억 달러로 평가되며, 2026년 1,614억 달러에서 2033년까지 2,584억 달러로 확대하며, 2026-2033년의 CAGR은 6.9%에 달할 것으로 예측됩니다.

북미가 시장을 주도하며, 2025년에는 41.7%라는 최대 점유율을 차지했습니다. 바이오의약품 제3자 물류(3PL) 업계는 바이오의약품 및 바이오시밀러의 상용화 확대, 온도 관리 및 GDP(의약품 유통 적정 기준)를 준수하는 물류 인프라에 대한 수요 증가, 제약사 및 생명공학 기업의 공급망 업무 아웃소싱 증가, 세포 치료 및 유전자 치료를 포함한 임상 시험과 첨단 치료법의 확대, 그리고 엔드투엔드 제품 가시화 및 규제 준수를 위한 디지털 공급망 기술에 대한 지속적인 투자에 힘입어 견고한 성장을 달성하고 있습니다.

전 세계 바이오의약품 유통의 복잡성에 더해, 온도 관리가 필요한 제품에 대한 엄격한 취급 요건과 국경을 넘는 의약품 무역의 확대가 맞물리면서, 제조사들은 운송, 창고 보관, 포장, 재고 관리, 콜드 체인 기능을 통합하여 제공하는 전문 제3자 물류(3PL) 제공업체와의 제휴를 추진하고 있습니다.

바이오의약품, 바이오시밀러 및 첨단 치료법의 급속한 확대는 여전히 시장 성장을 이끄는 주요 요인 중 하나입니다. 기존 의약품과 달리 바이오의약품은 제품의 효능을 유지하고 규제 준수를 보장하기 위해 공급망 전반에 걸쳐 전문적인 운송, 온도 관리된 보관, 검증된 포장 및 지속적인 모니터링이 필요합니다. 모노클로널 항체, 백신, 재조합 단백질, 그리고 세포·유전자 치료제의 상용화가 진행됨에 따라 GDP 인증을 받은 인프라와 글로벌 유통 네트워크를 갖춘 전문 물류 제공업체에 대한 수요가 크게 증가하고 있습니다.

또한 의약품 공급망 업무의 아웃소싱 확대 역시 시장 성장을 지원하는 또 다른 주요 촉진요인이 되고 있습니다. 제약 회사와 생명공학 기업은 유통 효율 최적화, 규제 준수 강화, 운영 비용 절감, 그리고 세계 시장에서 공급망의 회복탄력성 강화를 도모하기 위해 전문적인 제3자 물류 제공업체에 대한 의존도를 높이고 있습니다. 규제가 엄격한 바이오의약품 공급망을 관리하기 위해서는 콜드체인 관리, 통관 절차, 일련번호 부여, 재고 관리, 라스트마일 배송에 대한 전문적인 지식이 필요하므로 아웃소싱은 비용 대비 효과가 높고 확장성이 뛰어난 솔루션이 되고 있습니다. 물류 업계 전반에 걸친 전략적 투자와 인수합병(M&A) 역시 이러한 추세를 더욱 지원하고 있습니다. 예를 들어 2025년 3월, DHL은 임상시험 물류, 바이오의약품 유통 및 세포·유전자 치료제 운송 역량을 강화하기 위해 전문 의약품 물류 제공업체인 CryoPDP의 인수를 발표하며, 통합형 헬스케어 물류 포트폴리오와 전문적인 콜드체인 네트워크를 더욱 확대했습니다.

그러나 시장 성장은 온도 관리 인프라에 필요한 막대한 설비 투자, 전 세계 규제 준수에 대한 엄격한 요건, 그리고 국제 시장을 가로질러 극도로 민감한 바이오의약품을 운송하는 데 따르는 운영상의 복잡성으로 인해 제약을 받고 있습니다. 그럼에도 불구하고 첨단 치료법의 상용화 진전, 바이오의약품 파이프라인의 확대, 디지털 공급망 기술의 도입 확대, 그리고 GDP(Good Distribution Practice) 준수를 위한 콜드체인 인프라에 대한 지속적인 투자로 인해 바이오의약품 분야의 제3자 물류(3PL) 제공업체들에게는 장기적으로 큰 비즈니스 기회가 창출될 것으로 예상됩니다. 제약 제조사들이 안전하고 규정을 준수하며 전 세계에서 통합된 공급망 솔루션을 제공할 수 있는 전문 파트너에게 복잡한 물류 업무를 점점 더 많이 아웃소싱함에 따라 이 시장은 꾸준한 성장을 유지할 것으로 예상됩니다.

자주 묻는 질문

  • 바이오의약품 제3자 물류 시장 규모는 어떻게 예측되나요?
  • 바이오의약품 제3자 물류 시장에서 북미의 점유율은 어떻게 되나요?
  • 바이오의약품 제3자 물류 시장 성장을 이끄는 주요 요인은 무엇인가요?
  • 제약사들이 제3자 물류 제공업체에 의존하는 이유는 무엇인가요?
  • 바이오의약품 제3자 물류 시장의 주요 도전 과제는 무엇인가요?
  • 바이오의약품 제3자 물류 시장의 미래 전망은 어떤가요?

목차

제1장 연구 방법과 범위

제2장 개요

제3장 바이오의약품 제3자물류 시장 : 변수, 동향, 범위

제4장 바이오의약품 제3자물류 시장 : 공급망별 추정·동향 분석

제5장 바이오의약품 제3자물류 시장 : 서비스 유형별 추정·동향 분석

제6장 바이오의약품 제3자물류 시장 : 지역별 추정·동향 분석

제7장 경쟁 구도

KSA

Biopharmaceutical Third-Party Logistics Market Summary

The global biopharmaceutical third-party logistics market size was valued at USD 152.0 billion in 2025 and is projected to grow from USD 161.4 billion in 2026 to USD 258.4 billion by 2033, at a CAGR of 6.9% from 2026 to 2033. North America dominated the market, accounting for the largest share of 41.7% in 2025. The biopharmaceutical third-party logistics (3PL) industry is experiencing robust growth, driven by the expanding commercialization of biologics and biosimilars, increasing demand for temperature-controlled and GDP-compliant logistics infrastructure, rising outsourcing of supply chain operations by pharmaceutical and biotechnology companies, growth in clinical trials and advanced therapies including cell and gene therapies, and continuous investments in digital supply chain technologies for end-to-end product visibility and regulatory compliance.

The increasing complexity of global biopharmaceutical distribution, combined with stringent handling requirements for temperature-sensitive products and growing cross-border pharmaceutical trade, is encouraging manufacturers to partner with specialized third-party logistics providers offering integrated transportation, warehousing, packaging, inventory management, and cold chain capabilities.

The rapid expansion of biologics, biosimilars, and advanced therapies remains one of the primary factors driving market growth. Unlike conventional pharmaceuticals, biologics require specialized transportation, temperature-controlled storage, validated packaging, and continuous monitoring throughout the supply chain to preserve product efficacy and regulatory compliance. The growing commercialization of monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies has significantly increased the demand for specialized logistics providers with GDP-certified infrastructure and global distribution networks.

Furthermore, increasing outsourcing of pharmaceutical supply chain operations is another major driver supporting market expansion. Pharmaceutical and biotechnology companies are increasingly relying on specialized third-party logistics providers to optimize distribution efficiency, improve regulatory compliance, reduce operational costs, and enhance supply chain resilience across global markets. Managing highly regulated biopharmaceutical supply chains requires specialized expertise in cold chain management, customs clearance, serialization, inventory control, and last-mile delivery, making outsourcing a cost-effective and scalable solution. Strategic investments and acquisitions across the logistics industry further demonstrate this trend. For instance, in March 2025, DHL announced the acquisition of specialty pharmaceutical logistics provider CryoPDP to strengthen its capabilities in clinical trial logistics, biopharma distribution, and cell and gene therapy transportation, further expanding its integrated healthcare logistics portfolio and specialized cold chain network.

However, the market growth is constrained by the high capital investment required for temperature-controlled infrastructure, stringent global regulatory compliance requirements, and the operational complexity associated with transporting highly sensitive biopharmaceutical products across international markets. Nevertheless, increasing commercialization of advanced therapies, expanding biologics pipelines, growing adoption of digital supply chain technologies, and continued investments in GDP-compliant cold chain infrastructure are expected to create substantial long-term opportunities for biopharmaceutical third-party logistics providers. The market is expected to maintain steady growth as pharmaceutical manufacturers increasingly outsource complex logistics operations to specialized partners capable of delivering secure, compliant, and globally integrated supply chain solutions.

Global Biopharmaceutical Third-party Logistics Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopharmaceutical third-party logistics market report based on supply chain, service type, and region:

  • Supply Chain Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Cold Chain Logistics
  • Non-cold Chain Logistics
  • Service Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Transportation
    • Air Freight
    • Sea Freight
    • Overland
  • Warehousing and Storage
  • Other Services
  • Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Thailand
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Qatar
    • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Supply Chain
    • 1.2.2. Service Type
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Bottom-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Biopharmaceutical Third-Party Logistics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Technological Advancements in Logistics
      • 3.2.1.2. Growing Applications of Reverse Logistics in the Biopharmaceutical Industry
      • 3.2.1.3. Rising Demand for Cold Chain Logistics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Stringent Regulatory Framework
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Force Analysis
    • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Biopharmaceutical Third-Party Logistics Market: Supply Chain Estimates & Trend Analysis

  • 4.1. Biopharmaceutical Third-Party Logistics Market, By Supply Chain: Segment Dashboard
  • 4.2. Biopharmaceutical Third-Party Logistics Market, By Supply Chain: Movement Analysis
  • 4.3. Biopharmaceutical Third-Party Logistics Market Estimates & Forecasts, By Supply Chain, 2021 - 2033 (USD Million/Billion)
  • 4.4. Cold Chain Logistics
    • 4.4.1. Cold Chain Logistics Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.5. Non-cold Chain Logistics
    • 4.5.1. Non-cold Chain Logistics Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 5. Biopharmaceutical Third-Party Logistics Market: Service Type Estimates & Trend Analysis

  • 5.1. Biopharmaceutical Third-Party Logistics Market, By Service Type: Segment Dashboard
  • 5.2. Biopharmaceutical Third-Party Logistics Market, By Service Type: Movement Analysis
  • 5.3. Biopharmaceutical Third-Party Logistics Market Estimates & Forecasts, By Service Type, 2021 - 2033 (USD Million/Billion)
  • 5.4. Transportation
    • 5.4.1. Transportation Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.4.2. Air Freight
      • 5.4.2.1. Air Freight Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.4.3. Sea Freight
      • 5.4.3.1. Sea Freight Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 5.4.4. Overland
      • 5.4.4.1. Overland Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.5. Warehousing and Storage
    • 5.5.1. Warehousing and Storage Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.6. Other Services
    • 5.6.1. Other Services Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 6. Biopharmaceutical Third-Party Logistics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2025 & 2033
  • 6.3. North America
    • 6.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.3.2. U.S.
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.3.3. Canada
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.3.4. Mexico
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.4. Europe
    • 6.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.4.2. UK
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.4.3. Germany
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.4.4. France
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.4.5. Italy
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.4.6. Spain
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.4.7. Denmark
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.4.8. Sweden
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Competitive Scenario
      • 6.4.8.3. Regulatory Framework
      • 6.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.4.9. Norway
      • 6.4.9.1. Key Country Dynamics
      • 6.4.9.2. Competitive Scenario
      • 6.4.9.3. Regulatory Framework
      • 6.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.2. Japan
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.3. China
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.4. India
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.5. Australia
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.6. Thailand
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.5.7. South Korea
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.6. Latin America
    • 6.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.6.2. Brazil
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.6.3. Argentina
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 6.7. MEA
    • 6.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.7.2. South Africa
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.7.3. UAE
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.7.4. Saudi Arabia
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Competitive Scenario
      • 6.7.4.3. Regulatory Framework
      • 6.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Competitive Scenario
      • 6.7.5.3. Regulatory Framework
      • 6.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.7.6. Qatar
      • 6.7.6.1. Key Country Dynamics
      • 6.7.6.2. Competitive Scenario
      • 6.7.6.3. Regulatory Framework
      • 6.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 6.7.7. Oman
      • 6.7.7.1. Key Country Dynamics
      • 6.7.7.2. Competitive Scenario
      • 6.7.7.3. Regulatory Framework
      • 6.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 7. Competitive Landscape

  • 7.1. Key Participant Categorization
    • 7.1.1. Market Leaders
    • 7.1.2. Emerging Players
  • 7.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
  • 7.3. Company Profiles
    • 7.3.1. DHL International GmbH
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Financial Performance
      • 7.3.1.3. Service Benchmarking
      • 7.3.1.4. Strategic Initiatives
    • 7.3.2. SF Express
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Financial Performance
      • 7.3.2.3. Service Benchmarking
      • 7.3.2.4. Strategic Initiatives
    • 7.3.3. FedEx
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Financial Performance
      • 7.3.3.3. Service Benchmarking
      • 7.3.3.4. Strategic Initiatives
    • 7.3.4. United Parcel Service of America, Inc.
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Service Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Cencora, Inc.
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Service Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. DB Schenker
      • 7.3.6.1. Company Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Service Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. Kuehne and Nagel
      • 7.3.7.1. Company Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Service Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Kerry Logistics Network Limited
      • 7.3.8.1. Company Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Service Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. Agility Public Warehousing Company K.S.C.P.
      • 7.3.9.1. Company Overview
      • 7.3.9.2. Financial Performance
      • 7.3.9.3. Service Benchmarking
      • 7.3.9.4. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기